You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Studies show that pain and anxiety from shocks can lead to decreased quality of life and participation in normal activities.1 Furthermore, these shocks can lead to unnecessary hospital admissions,2 which can result in increased costs and resource usage.
SmartShock™ 2.0 Technology reduces the incidence of inappropriate shocks while maintaining sensitivity.3,4 In fact, 98.5% of dual chamber and triple chamber patients, and 97.5% of single chamber patients were free from inappropriate shocks at one year post-implant.2
Graph is a summary of the PainFree SST study.
Wathen MS, et al. Circulation. 2004;110:2591-2596.
Volosin KJ, et al. J Cardiovasc Electrophysiol. 2011;22:280-289.
Protecta Clinical Study, Medtronic data on file.